P062 DOSE ESCALATION WITH ORIGINATOR INFLIXIMAB OR COMBINATION THERAPY WITH ORIGINATOR INFLIXIMAB AND IMMUNOMODULATORS SIGNIFICANTLY INCREASES RISK FOR SERIOUS ADVERSE EVENTS IN PEDIATRIC IBD – THE DEVELOP EXPERIENCE
Veereman, Gigi, Busse, Christopher, Wang, Yanli, Izanec, JamesVolume:
156
Language:
english
Journal:
Gastroenterology
DOI:
10.1053/j.gastro.2019.01.119
Date:
February, 2019
File:
PDF, 1.10 MB
english, 2019